The Effectiveness of a Diverse COVID-19 Vaccine Portfolio and Its Impact on the Persistence of Positivity and Length of Hospital Stays: The Veneto Region's Experience.
COVID-19
COVID-19 vaccines
SARS-CoV-2
Veneto region
length of hospital stay
multivariate regression
persistence of positivity
survival analysis
vaccine effectiveness
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
11 Jan 2022
11 Jan 2022
Historique:
received:
20
12
2021
revised:
09
01
2022
accepted:
10
01
2022
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
23
1
2022
Statut:
epublish
Résumé
The vaccination campaign for the Veneto region (northeastern Italy) started on 27 December 2020. As of early December 2021, 75.1% of the whole Veneto population has been fully vaccinated. Vaccine efficacy has been demonstrated in many clinical trials, but reports on real-world contexts are still necessary. We conducted a retrospective cohort study on 2,233,399 residents in the Veneto region to assess the reduction in the COVID-19 burden, taking different outcomes into consideration. First, we adopted a non-brand-specific approach borrowed from survival analysis to estimate the effectiveness of vaccination against SARS-CoV-2 in preventing infections, hospitalizations, and deaths. We used
Identifiants
pubmed: 35062767
pii: vaccines10010107
doi: 10.3390/vaccines10010107
pmc: PMC8777781
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Veneto Regional Authority
ID : DGR 1643 of 24/11/2020. "Project to assess the prevalence and spread of SARS-Cov-2 in the population"
Références
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243356
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Euro Surveill. 2021 Jun;26(25):
pubmed: 34169819
Vaccines (Basel). 2021 Nov 24;9(12):
pubmed: 34960133
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Eur J Pediatr. 2021 Feb;180(2):307-322
pubmed: 32803422
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
Vaccines (Basel). 2021 Nov 24;9(12):
pubmed: 34960126
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987